Trial Profile
A Pharmacoepidemiological Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Practice in Sweden
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 28 Sep 2021
Price :
$35
*
At a glance
- Drugs Rivaroxaban (Primary) ; Aspirin; Clopidogrel; Dipyridamole; Prasugrel; Ticagrelor; Ticlopidine; Warfarin
- Indications Deep vein thrombosis; Embolism; Pulmonary embolism; Stroke; Venous thromboembolism
- Focus Adverse reactions; Therapeutic Use
- Sponsors Bayer
- 19 Oct 2020 Status changed from active, no longer recruiting to completed.
- 22 Apr 2020 Planned End Date changed from 1 Apr 2020 to 30 Sep 2020.
- 15 Nov 2019 Status changed from recruiting to active, no longer recruiting.